新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 抑郁症 » Transl Psychiat:新血液测试可帮助诊断抑郁症

Transl Psychiat:新血液测试可帮助诊断抑郁症

来源:生物谷 2014-09-23 10:07

2014年9月23日 讯 /生物谷BIOON/ --世界卫生组织已确定,抑郁症是世界范围内引发残疾的首要原因。美国西北大学研究人员开发出一种新的血液测试(即测量血液中九种不同的RNA分子水平)可帮助诊断抑郁症,这九种不同的RNA分子似乎在健康者和抑郁症患者之间显著不同。

但该新的血液测试运用于临床,仍然有很长的路要走。这一测试的相关研究发表在Translational Psychiatry杂志上,研究人员已在小样本人群中,运用该血液测试准确地诊断抑郁症,研究人员希望在将来能更广泛的使用这一新血液测试。除了准确诊断抑郁症,该血液测试技术还能够知道谁将可以受益于谈话疗法。

研究人员招募了32例患有重度抑郁症的患者,以及32位非抑郁症患者(对照组)。对抑郁症患者进行18周的认知行为疗法后,研究小组能够确定针对治疗反应良好的患者血液测试中,哪些RNA分子水平是变化的。

治疗期间结束后,大约40%的病人不再沮丧。有趣的是,得到恢复的患者血液中RNA水平有一个独特的“指纹”。这表明,试验或许能揭示谁将可以受益于这种形式的治疗。

目前,根据一些病人的行为和情绪,治疗师进行主观、单对单的观察诊断抑郁症。该血液测试将可最终能够测试疾病的严重程度或治疗方向,而这具体则取决于血液测试中标志物的类型等级。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy

E E Redei,et al.

An objective, laboratory-based diagnostic tool could increase the diagnostic accuracy of major depressive disorders (MDDs), identify factors that characterize patients and promote individualized therapy. The goal of this study was to assess a blood-based biomarker panel, which showed promise in adolescents with MDD, in adult primary care patients with MDD and age-, gender- and race-matched nondepressed (ND) controls. Patients with MDD received cognitive behavioral therapy (CBT) and clinical assessment using self-reported depression with the Patient Health Questionnaire–9 (PHQ-9). The measures, including blood RNA collection, were obtained before and after 18 weeks of CBT. Blood transcript levels of nine markers of ADCY3, DGKA, FAM46A, IGSF4A/CADM1, KIAA1539, MARCKS, PSME1, RAPH1 and TLR7, differed significantly between participants with MDD (N=32) and ND controls (N=32) at baseline (q< 0.05). Abundance of the DGKA, KIAA1539 and RAPH1 transcripts remained significantly different between subjects with MDD and ND controls even after post-CBT remission (defined as PHQ-9 <5). The ROC area under the curve for these transcripts demonstrated high discriminative ability between MDD and ND participants, regardless of their current clinical status. Before CBT, significant co-expression network of specific transcripts existed in MDD subjects who subsequently remitted in response to CBT, but not in those who remained depressed. Thus, blood levels of different transcript panels may identify the depressed from the nondepressed among primary care patients, during a depressive episode or in remission, or follow and predict response to CBT in depressed individuals.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库